HDAC10 histone deacetylase 10
ENSG00000100429 · protein coding · Open Targets profile
Polyamine deacetylase (PDAC), which acts preferentially on N(8)-acetylspermidine, and also on acetylcadaverine and acetylputrescine (PubMed:28516954). Exhibits attenuated catalytic activity toward N(1),N(8)-diacetylspermidine and very low activity, if any, toward N(1)-acetylspermidine (PubMed:28516954). Histone deacetylase activity has been observed in vitro (PubMed:11677242, PubMed:11726666, PubMed:11739383, PubMed:11861901). Has also been shown to be involved in MSH2 deacetylation (PubMed:26221039). The physiological relevance of protein/histone deacetylase activity is unclear and could be very weak (PubMed:28516954). May play a role in the promotion of late stages of autophagy, possibly autophagosome- lysosome fusion and/or lysosomal exocytosis in neuroblastoma cells (PubMed:23801752, PubMed:29968769). May play a role in homologous recombination (PubMed:21247901). May promote DNA mismatch repair (PubMed:26221039). {ECO:0000269|PubMed:11677242, ECO:0000269|PubMed:11726666, ECO:0000269|PubMed:11739383, ECO:0000269|PubMed:11861901, ECO:0000269|PubMed:21247901, ECO:0000269|PubMed:23801752, ECO:0000269|PubMed:26221039, ECO:0000269|PubMed:28516954, ECO:0000269|PubMed:29968769}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, High-Quality Ligand, Druggable Family
- PROTAC
- Database Ubiquitination, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 1.093500018119812 (upper bound 1.302899956703186). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 119 registry trials, updated in the last three years, of the most advanced drugs against HDAC10 (entinostat, givinostat, romidepsin, panobinostat lactate, belinostat, panobinostat, abexinostat, tacedinaline, fimepinostat, quisinostat), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Yuankai SHICancer Institute and Hospital, Chinese Academy of Medical Sciences · 3 of 3 trials Phase 2+Ph2NCT03936153 · Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)brief
- Steven HorwitzMemorial Sloan Kettering Cancer Center · 2 of 3 trials Phase 2+
- Roisin M ConnollyECOG-ACRIN Cancer Research Group · 1 of 3 trials Phase 2+Ph3NCT02115282 · Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastaticbrief
- Nilofer AzadJohns Hopkins University · 1 of 2 trials Phase 2+
- Ahmad TarhiniMoffitt Cancer Center · 1 of 1 trials Phase 2+
- Alessandro RambaldiAzienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy · 1 of 1 trials Phase 2+
- Alison MoskowitzMemorial Sloan Kettering Cancer Center · 1 of 1 trials Phase 2+
- Bristol-Myers SquibbBristol-Myers Squibb · 1 of 1 trials Phase 2+
- Connie W BatleviMemorial Sloan Kettering Cancer Center · 1 of 1 trials Phase 2+
- Craig PortellUniversity of Virginia · 1 of 1 trials Phase 2+
- Daniel R KuritzkesMassachusetts General Hospital · 1 of 1 trials Phase 2+
- David S SchrumpNational Cancer Institute (NCI) · 1 of 1 trials Phase 2+
- David S. SchrumpNational Cancer Institute (NCI) · 1 of 1 trials Phase 2+
- Dennis SlamonUniversity of California, Los Angeles · 1 of 1 trials Phase 2+
- Edwin ChoyMassachusetts General Hospital · 1 of 1 trials Phase 2+
Registry trials of entinostat, givinostat, romidepsin, panobinostat lactate, belinostat, panobinostat, abexinostat, tacedinaline, fimepinostat, quisinostat updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 93 of 117 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 2 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
124 trials of drugs against HDAC10 were stopped early; 24 give no reason
Terminated, withdrawn and suspended interventional trials of entinostat, givinostat, romidepsin, panobinostat lactate, belinostat, panobinostat, abexinostat, tacedinaline, fimepinostat, quisinostat, CUDC-101, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 124.
- terminated · 2026-09-16 · Jennifer Amengual · Romidepsin“Lack of funding and recruitment complications caused by COVID-19”
- terminated · 2026-09-04 · University of Utah · Belinostat“No accrual in one year”
- terminated · 2026-05-06 · University of Michigan Rogel Cancer Center · Romidepsin“Lack of accrual”
- terminated · 2026-03-03 · National Cancer Institute (NCI) · Belinostat“Drug supply issues”
- terminated · 2026-03-02 · Antonio Fojo · Entinostat“Lack of funding and drug supply”
- terminated · 2026-01-30 · National Cancer Institute (NCI) · Belinostat“Other - Adverse Events”
- withdrawn · 2025-09-11 · Judit Pich · matched by the registry's drug synonyms“The clinical trial was discontinued prior to initiation due to the withdrawal of the vaccine manufacturer (etherRNA) from the research consortium. As a result, the study could not proceed as originally planned.”
- terminated · 2025-06-08 · Columbia University · Panobinostat 15 MG“FDA withdrew approval of the new drug application (NDA) for panobinostat as of March 24, 2022 because it was not feasible for the company to complete the required postmarketing clinical trials.”
- terminated · 2025-05-26 · Mayo Clinic · Belinostat, Romidepsin“funding - sponsor filing Chapter 11 bankruptcy”
- terminated · 2025-05-16 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Romidepsin“Closed by Sponsor”
- terminated · 2025-05-02 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Panobinostat“Arm A - reached goal; Arm B - poor accrual”
- terminated · 2025-03-20 · Roberto Pili · Entinostat“Genentech has closed the study due to lack of data with Atezo”
- terminated · 2025-02-24 · Australian & New Zealand Children's Haematology/Oncology Group · Panobinostat“Drug supply”
- terminated · 2025-02-10 · Biodexa Pharmaceuticals · matched by the registry's drug synonyms“Strategic decision”
- terminated · 2024-09-03 · Roberto Pili · Entinostat“Funder halted development of compound in this disease”
- terminated · 2024-08-22 · Columbia University · RomiDEPsin 10 MG/M2, Romidepsin 14 MG/M2“PI left institution”
- withdrawn · 2024-08-05 · National Cancer Institute (NCI) · Entinostat“No enrollment”
- terminated · 2024-06-06 · Abdullah Khan · Panobinostat Lactate“PI Decision”
- terminated · 2024-03-25 · UNC Lineberger Comprehensive Cancer Center · Entinostat“Funding withdrawn.”
- terminated · 2024-03-04 · OHSU Knight Cancer Institute · Panobinostat“Low accrual”
- terminated · 2024-02-15 · Dana-Farber Cancer Institute · Panobinostat“Withdrawal of support from BMS”
- terminated · 2023-07-19 · Italfarmaco · matched by the registry's drug synonyms“As no safety warnings were detected, Interim analysis from the first 40 patients recommends to stop the trial for futility”
- terminated · 2023-07-06 · Syndax Pharmaceuticals · Entinostat“Due to business reasons, enrollment on the study was halted and the study terminated. The decision to close enrollment was not due to any safety concern.”
- terminated · 2023-06-28 · ECOG-ACRIN Cancer Research Group · matched by the registry's drug synonyms“The study was terminated on May 17, 2006 due to slow accrual.”
- withdrawn · 2023-05-18 · Dana-Farber Cancer Institute · matched by the registry's drug synonyms“On hold”
Paediatric incentives and obligations for HDAC10's drugs
For entinostat, givinostat, romidepsin, panobinostat lactate, belinostat, panobinostat, abexinostat, tacedinaline, fimepinostat, quisinostat, CUDC-101: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · HDAC10 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000223656 (givinostat, Treatment of polycythaemia vera): W: decision granting a waiver in all age groups for all conditions or indications, 3 Jan 2025; EMEA-000551-PIP04-21-M03 (givinostat, Treatment of Duchenne muscular dystrophy): PM: decision on the application for modification of an agreed PIP, 8 Mar 2024; EMEA-001023-PIP01-10 (romidepsin, Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)): W: decision granting a waiver in all age groups for all conditions or indications, 3 Feb 2011; EMEA-000551-PIP01-09 (givinostat, Juvenile idiopathic arthritis): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 29 Jan 2010Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/12/1063 expired 8 Nov 2012: Treatment of multiple myeloma; EU/3/12/1009 positive 4 Jul 2012: Treatment of Duchenne muscular dystrophy; EU/3/10/732 positive 10 Jun 2010: Treatment of Hodgkin's lymphoma; EU/3/22/2660 withdrawn 18 Jul 2022: Treatment of glioma; +8 moreRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Duvyzat: authorised since 6 Jun 2025, orphan medicine, conditional; Farydak: authorised since 28 Aug 2015; Istodax: refused, orphan medicineRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of entinostat, givinostat, romidepsin, panobinostat lactate, belinostat, panobinostat, abexinostat, tacedinaline, fimepinostat, quisinostat, cudc-101Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 37 interventional studies of entinostat, givinostat, romidepsin, panobinostat lactate, belinostat, panobinostat, abexinostat, tacedinaline, fimepinostat, quisinostat, cudc-101 include patients under 18; 6 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 12 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.